ERBB2 and breast carcinoma: In 2022, the American Society of Clinical Oncology produced updated guidelines on the management of brain metastases in patients with HER2-positive breast cancer and came to the conclusion that there were insufficient data to recommend for or against routine magnetic resonance imaging to screen for brain metastases [13].